

Supplementary Table S3. The distribution of thyroid tumors in surgical specimens in each country

	FA	HCA	NIFTP	all PTC	PMC (≤1cm)	PTC (>1cm)	FTC	HCC	Other borderline neoplasm ^a	Other malignancy ^b	Non-neoplastic
Japan (n=1,840)	146 (7.9)	34 (1.8)	4 (0.2)	888 (48.3)	233 (12.7)	655 (35.6)	54 (2.9)	10 (0.5)	52 (2.8)	60 (3.3)	592 (32.2)
India (n=612)	43 (7)	7 (1.1)	11 (1.8)	289 (47.2)	29 (4.7)	260 (42.5)	19 (3.1)	5 (0.8)	3 (0.5)	57 (9.3)	178 (29.1)
Taiwan (n=638)	20 (3.1)	13 (2.0)	4 (0.6)	311 (48.7)	116 (18.2)	195 (30.6)	15 (2.4)	2 (0.3)	17 (2.7)	7 (1.1)	249 (39)
Korea (n=8,076)	168 (2.1)	62 (0.8)	30 (0.4)	6,788 (84.1)	4,199 (52)	2,589 (32.1)	77 (1)	30 (0.4)	3 (0)	114 (1.4)	804 (10)
China (n=6,902)	132 (1.9)	37 (0.5)	17 (0.2)	5,371 (77.8)	3,715 (53.8)	1,656 (24)	41 (0.6)	6 (0.1)	64 (0.9)	63 (0.9)	1,171 (17)
Total (n=18,068)	509 (2.8)	153 (0.8)	66 (0.4)	13,647 (75.5)	8,292 (45.9)	5,355 (29.6)	206 (1.1)	53 (0.3)	139 (0.8)	301 (1.7)	2,994 (16.6)
p-value ^c	>.999	>.999	<.001	>.999	<.001	.020	>.999	>.999	<.001	<.001	>.999
p-value ^d	<.001	.762	>.999	>.999	<.001	.210	>.999	>.999	>.999	.040	.020
p-value ^e	<.001	<.001	>.999	<.001	<.001	.030	<.001	>.999	<.001	<.001	<.001
p-value ^f	<.001	>.999	>.999	<.001	<.001	<.001	<.001	<.001	<.001	<.001	<.001
p-value ^g	.020	>.999	.700	>.999	<.001	<.001	>.999	>.999	.020	<.001	<.001
p-value ^h	<.001	>.999	<.001	<.001	<.001	<.001	<.001	.930	.060	<.001	<.001
p-value ⁱ	<.001	.590	<.001	<.001	<.001	<.001	<.001	<.001	>.999	<.001	<.001
p-value ^j	.780	.010	>.999	<.001	<.001	>.999	.010	>.999	<.001	>.999	<.001
p-value ^k	.360	<.001	.960	<.001	<.001	<.001	<.001	>.999	<.001	>.999	<.001
p-value ^l	>.999	.710	>.999	<.001	.250	<.001	.130	<.001	<.001	.050	<.001

Values are presented as number (%) unless otherwise indicated.

For comparison between each country, chi-square test was used. Corrections for multiple testing are performed with Bonferroni method and adjusted p-values are presented.

FA, follicular adenoma; HCA, Hurthle cell adenoma; FTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC, papillary thyroid carcinoma; PMC, papillary microcarcinoma; FTC, follicular thyroid carcinoma; HCC, Hurthle cell carcinoma.

^aIncluding well differentiated carcinoma, not otherwise specified, well differentiated tumor of uncertain malignant potential, follicular tumor of uncertain

malignant potential and hyalinizing trabecular tumor; ^bIncluding poorly differentiated thyroid carcinoma, anaplastic thyroid carcinoma, medullary carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia, malignant lymphoma and sarcoma; ^cJapan versus India; ^dJapan versus Taiwan; ^eJapan versus Korea; ^fJapan versus China; ^gIndia versus Taiwan; ^hIndia versus Korea; ⁱIndia versus China; ^jTaiwan versus Korea; ^kTaiwan versus China; ^lKorea versus China.